Taro NonSpil
This article was originally published in The Tan Sheet
Executive Summary
Recent in-store demonstrations at Wal-Mart of Taro Pharmaceuticals' NonSpil drug delivery system were "met with huge and great reception from consumers," CFO Kevin Connelly comments at CIBC World Markets Healthcare Conference in New York City Nov. 12. Firm may conduct more demonstrations in Wal-Mart stores later this year or early next year, Connelly says. Taro is working on licensing agreements for NonSpil, the exec reports, adding that the firm will "have more growth opportunity...to license it on the prescription side" as possibility to extend the patent life of Rx drugs (1"The Tan Sheet" Sept. 15, 2003, p. 4). Sales of Taro's ElixSure line of cough/cold medicines for children, which was shipped in June and uses the NonSpil technology, are doing "very well," though "it is too early to tell" if the launch is a complete success, according to Connelly...
You may also be interested in...
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.